Document is current
Any future updates will be listed below
-
Authors
Coquan, Elodie https://orcid.org/0000-0002-9497-0424
Clarisse, Bénédicte
Lequesne, Justine
Brachet, Pierre-Emmanuel
Nevière, Zoé
Meriaux, Emeline
Bonnet, Isabelle
Castera, Marie
Goardon, Nicolas
Boutrois, Jeremy
Travers, Romain
Joly, Florence
Grellard, Jean-Michel
Thiery-Vuillemin, Antoine
- License Information
-
More Information
Article History
Received: 23 December 2021
Accepted: 22 October 2022
First Online: 24 November 2022
Declarations
:
: This study has received ethical approval from the <i>Comité de Protection des Personnes EST IV</i> in December 2020 (N° EudraCT: 2020–001105-24) and from National Agency for Medical and Health products Safety (Reference: MEDAECNAT-2020–08-00012_2020-001105–24) in October 2020. All patients will be proposed to participate by the medical oncologists who will give them an information file; all patients will give their written informed consent before any study-related assessment start.
: Not applicable.
: This trial (NCT04678362) is granted by Pfizer SAS that also provides Talazoparib and Avelumab for participating patients.None of the authors has a conflict of interest to declare.
